FLUDARA

LOE Approaching

fludarabine phosphate

NDAINJECTIONINJECTABLEPriority Review
Approved
Apr 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT07228273Phase 2Recruiting

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Started Dec 2025
102 enrolled
Acute Myeloid LeukemiaMyelodysplastic Syndrome
NCT05780879Phase 2Recruiting

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

Started Jun 2024
20 enrolled
Secondary Acute Myeloid Leukemia
NCT05139004Phase 1Active Not Recruiting

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Started Jul 2022
NCT04425655Phase 2Terminated

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

Started Aug 2020
2 enrolled
Acute Myeloid Leukemia, AdultAMLAML, Adult
NCT04285567Phase 3Completed

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Started May 2020
166 enrolled
Chronic Lymphocytic Leukemia (CLL)